Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 12Ovarian Neoplasms 8Fallopian Tube Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2

Interventions

pembrolizumab 44Carboplatin 35Paclitaxel 27Specimen Handling 18Cyclophosphamide 16Capecitabine 16Magnetic Resonance Spectroscopy 14sacituzumab govitecan 13Gemcitabine 13Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9olaparib 8Doxorubicin 8Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Fulvestrant 4Epirubicin 4Bevacizumab 4veliparib 3famitinib 3abemaciclib 3Vinorelbine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Disulfides × 90 days × Clear all
NCT03606967 2026-06-12

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡